小智港股覆盤 | 7月7日
今日，港股三大指數漲跌互現。截止收盤，恆生指數漲0.26%，報21643點。國企指數跌0.09%，報7538點。恆生科技指數跌0.45%，報4780點。市場約771只個股上漲，812只個股下跌。成交額突破1120.58億港幣，和昨天同期相比下跌20.67%。南下資金淨流出6096.95萬港幣。
盤面上，海運板塊漲幅較前。金輝集團、潤利海事、中遠海控等多股漲超5%；東方海外國際、海豐國際等多股漲超3%。潤利海事擬於9月20日派年度末期股息每股0.02港元；中遠海控(601919.SH)：預計上半年實現淨利潤約647.16億元，息稅前利潤增長約92.08%；海通國際：首予東方海外國際“優於大市”評級，目標價377.04港元；瑞信：東方海外及中遠海控次季業績穩健，首選海豐。
航空板塊大漲靠前。中國國航漲超4%；中國南方航空股份、國泰航空等多股漲超3%；中國東方航空股份漲超1%。航空股尾盤走高，國航、南航均漲超4%，香港暫緩個別航線熔斷機制；中國南方航空股份：累計已有101億元南航轉債轉換成A股股票；航空股午後全線走高，國泰航空漲3.26%。
菸草板塊漲幅較前。思摩爾國際漲超3%。思摩爾國際：交換財產於6月22日獲公司派息1053.78萬港元。
生物科技板塊走低。再鼎醫藥-B跌超7%；永泰生物-B、中國再生醫學等多股跌超6%；百濟神州、雲頂新耀-B等多股跌超5%。百濟神州高開11.73%，自研藥PD-1刷新食管鱗癌3期試驗最長生存記錄。
醫療設備板塊走低。先瑞達醫療-B跌超7%；貝康醫療-B、沛嘉醫療-B等多股跌超6%；微創醫療、康德萊醫械等多股跌超5%。先瑞達醫療-B再升8%、近一月累漲60%，國信上調公司盈利預測。
信息技術板塊走弱。PLATT NERA跌超9%；萬國數據-SW跌超5%；移卡、遠見控股、伊登軟件等多股跌超2%。
uSMART智能寫手的信息、數據均來自媒體公開報道，智能寫手不能保證其完全準確，內容僅供參考，不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
